Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tilarginine in cardiogenic shock after acute myocardial infarction
2005-000412-27Phase 3Completed
- Sponsor
- Arginox Pharmaceuticals, Inc.
- Start
- Jun 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI) comparing Tilarginine acetate with Placebo (2 arms). Primary endpoint: All-cause mortality at 30 days. Started Jun 2005; status: completed.
02
Drugs
NG-monomethyl-L-arginine
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2005-000412-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000412-27.